XML 46 R33.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

6 Months Ended

Sep. 30, 2023

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:


	Three Months Ended September 30,						Six Months Ended September 30,
	2023			2022			2023			2022
	(in thousands)						(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	49,999		$	75,659		$	110,863		$	140,172
Total revenue	$	49,999		$	75,659		$	110,863		$	140,172
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(6,673	)	$	2,324		$	(12,275	)	$	(14,673	)
Therapeutics Adjusted EBITDA		(26,224	)		(18,663	)		(57,363	)		(37,128	)
Unallocated Corporate (2)		(12,156	)		(13,316	)		(25,215	)		(27,568	)
Total Adjusted EBITDA	$	(45,053	)	$	(29,655	)	$	(94,853	)	$	(79,369	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(75,270	)	$	(66,065	)	$	(179,894	)	$	(155,597	)
Adjustments:
Interest income, net		(3,752	)		(1,392	)		(8,059	)		(1,637	)
Other (income) expense, net		(145	)		687			(477	)		1,122
Provision for (benefit from) income taxes		36			(1,271	)		36			(1,525	)
Depreciation and amortization		4,474			5,152			8,951			10,256
Amortization of acquired intangible assets		3,638			4,267			7,277			8,582
Stock-based compensation expense		23,741			28,967			74,840			59,430
Loss on disposition of Lemonaid Health Limited and transaction-related costs (3)		2,127			—			2,375			—
Litigation settlement cost		98			—			98			—
Total Adjusted EBITDA	$	(45,053	)	$	(29,655	)	$	(94,853	)	$	(79,369	)

(1)

There was no Therapeutics revenue for the three and six months ended September 30, 2023 and 2022.

(2)

Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

(3)

Refer to Note 17, “Disposition of Subsidiary” for additional information.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:


	Three Months Ended September 30,									Six Months Ended September 30,
	2023					2022				2023				2022
	(in thousands)									(in thousands)
Consumer and Research Services Segment Revenue:
Customer C (1) (2)	$	13,040		26	%	$	17,057	23	%	$	22,751	21	%	$	26,684	19	%
Customer B (3)	*		*			$	14,925	20	%	$	11,753	11	%	$	23,190	17	%

* less than 10%

(1)

Customer C is a reseller.

(2)

Customer C revenues are primarily in the United States.

(3)

Customer B revenues are in the U.K.